Skip to content

Postoperative Pain Control by Use of Many Drugs in Small Doses Intrathecally

Multimodal Intrathecal Analgesia for Cesarean Section

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05186454
Enrollment
60
Registered
2022-01-11
Start date
2021-05-23
Completion date
2022-02-15
Last updated
2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Operative Pain

Keywords

Intrathecal morphine, midazolam, dexamethasone, cesarean section

Brief summary

Cesarean section is one of the painful operations that require adequate postoperative analgesia. Patients are divided into two groups: Multimodal (DMM) group ( 30 patients): patients will receive spinal anesthesia with 10-12.5 mg bupivacaine and 1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam. Morphine (M) group (30 patients): patients will receive spinal anesthesia with 10-12.5 mg bupivacaine and 1 ml containing 200 µg morphine

Interventions

DRUGMorphine Sulfate

analgesia

DRUGBupivacaine

Analgesia

DRUGdexamethasone, morphine, midazolam

1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* ASA I-II * Age 20-40 years. * Pregnant women with living fetus. * Body mass index 20- 35 kg/m2.

Exclusion criteria

* Patient refusal. * Age \< 20 or \> 40 years * Body mass index \< 20 or \> 35. * Contraindication to spinal anesthesia (severe mitral or aortic stenosis, coagulopathy, Systemic or local infection, increased intracranial pressure and hypovolemia). * Placental abnormalities: placental abruption, placenta previa or accrete. * Allergy to drugs used in the study.

Design outcomes

Primary

MeasureTime frameDescription
1st analgesic requirement24 hoursThe first time of supplemental analgesic need postoperatively

Secondary

MeasureTime frameDescription
Analgesic consumption24 hoursTotal analgesic consumption
Post operative pain24 hoursVisual Analog Scale(0-10 with 0 is no pain and 10 is maximum intolerable pain)
Side effects24 hours1. Pruritus (assessed the number of patients suffering from pruritus and grading the degree as follow:Mild= Itching is a minor concern, Moderate = Itching is a primary concern, but bearable,Severe= Unbearable; patient need anti-histaminic treatment. 2. Nausea and/or vomiting(assessed on 4 grade scales: 0= no symptoms present, 1 =mild nausea with no need for pharmacological treatment, 2= moderate nausea that required treatment (ondansetron 4 mg), 3= severe nausea that is resistant to treatment). 3-Sedation (assessed on 4 grade scale: 1-awake and alert, 2 -slightly drowsy, easily aroused, 3 -drowsy, drifts off to sleep during conversation, 4 -somnolent, minimal, or no response to physical stimulation). 4- Respiratory depression whether present or not(Respiratory depression was defined as a respiratory rate ≤10/min.)

Countries

Egypt

Contacts

Primary ContactFouad Soliman
fouad_soliman@med.sohag.edu.eg01113815186

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026